Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Letrozole 25Fulvestrant 25Specimen Handling 19ribociclib 16Capecitabine 16pembrolizumab 14palbociclib 14Paclitaxel 14Trastuzumab 13Carboplatin 13exemestane 12abemaciclib 12Tamoxifen 12Anastrozole 12Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 8pertuzumab 8Biopsy 8Goserelin 7inavolisib 6giredestrant 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6patritumab deruxtecan 5eribulin 5elacestrant 5Taxes 5Standard of Care 5Radiotherapy 5Gonadotropin-Releasing Hormone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Electrocardiography × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡